CTOs on the Move

Mirna Therapeutics

www.mirnarx.com

 
Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.mirnarx.com
  • 2150 Woodward St. Suite 100
    Austin, TX USA 78744
  • Phone: 512.901.0900

Executives

Name Title Contact Details

Funding

Mirna Therapeutics raised $42M on 05/01/2015

Similar Companies

TECHNE CORP /MN/

TECHNE CORP /MN/ is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enzyme by Design

A protein engineering startup passionate about developing safer cancer therapeutics

Stone Clinical Laboratories

The most innovative, patient and provider focused preventative diagnostic laboratory in the industry

Emulate

We work at the intersection of biology, engineering, and design, developing technologies that emulate human biology. Our products are enabling a new era of precision medicine and the development of applications for personalized health. Our Human Emulation System, which uses Organs-on-Chips technology, is being used by industry, government, and academia to understand how different diseases, medicines, chemicals and foods affect human health. The system offers researchers a new standard for predicting human response — with greater precision and control than today`s cell culture or animal-based experimental methods. We are also leading a bold, new precision medicine initiative with our clinical partners. Named "Patient-on-a-Chip," the program is developing personalized chips with patients` own cells. This initiative will help transform the way each of us understands our own bodies and manages our own health. Research conducted using our Organ-Chips has been published in high-impact scientific journals, including Science. In addition, Organ-Chips have been acquired by the Museum of Modern Art (MoMA) in New York for their permanent collection, and have also been awarded Product Design of the Year 2015 by London`s Design Museum. Our founding team pioneered the original Organs-on-Chips technology during their residency within the Wyss Institute for Biologically Inspired Engineering at Harvard University.

MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients. In addition, MannKind is applying our novel technologies and services to support partner development efforts.